Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis-Reference-Cited by-同舟云学术

Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis

Published:2016-10 Issue:10 Volume:31 Page:1757-1765
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Kao Jia-Horng¹,Tung Shui-Yi²³,Lee Younjae⁴,Thongsawat Satawat⁵,Tanwandee Tawesak⁶,Sheen I.-Shyan³,Wu Jinzi J.⁷,Li Hui⁸,Brennan Barbara J.⁹,Zhou Julian⁸,Le Pogam Sophie¹⁰,Najera Isabel¹¹,Thommes James A.¹⁰,Hill George¹⁰

Affiliation:

1. Graduate Institute of Clinical Medicine and Hepatitis Research Center; National Taiwan University and Hospital; Taipei Taiwan

2. Department of Gastroenterology, Chang Gung Memorial Hospital; Chia Yi Taiwan

3. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, College of Medicine; Chang Gung University; Taoyuan Taiwan

4. Pusan Paik Hospital; Inje University; Pusan Korea

5. Faculty of Medicine; Chiang Mai University; Chiang Mai Thailand

6. Department of Medicine; Siriraj Hospital; Bangkok Thailand

7. Ascletis BioScience; Hangzhou China

8. Roche Product Development; Shanghai China

9. Roche Translational and Clinical Research Center; New York New York USA

10. Genentech; South San Francisco California USA

11. Roche Pharma and Early Development; Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd; Basel Switzerland

Funder

F. Hoffmann-La Roche Ltd. Support

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.13374/fullpdf

Reference27 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J. Hepatol.,2014

2. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd;Hepatology,2013

3. Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus;AASLD/IDSA HCV Guidance Panel;Hepatology,2015

4. EASL recommendations on treatment of hepatitis C 2015;European Association for Study of Liver;J. Hepatol.,2015

5. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients;Gane;J. Hepatol.,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China;Medicine;2021-06-18

2. Effects of miR-185-5p on replication of hepatitis C virus;Open Life Sciences;2021-01-01

3. Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir‐boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection;Journal of Medical Virology;2020-06-29

4. Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C;Journal of Clinical and Translational Hepatology;2019-07-22

5. Danoprevir: First Global Approval;Drugs;2018-08